Human hepatocyte PNPLA3 148M exacerbates rapid non-alcoholic steatohepatitis development in chimeric mice
M. Kabbani, E. Michailidis, S. Steensels, C. G. Fulmer, J. M. Luna, J. Le Pen, M. Tardelli, B. Razooky, I. Ricardo-Lax, C. Zou, B. Zeck, A. F. Stenzel, C. Quirk, L. Foquet, A. W. Ashbrook, W. M. Schneider, S. Belkaya, G. Lalazar, Y. Liang, M. Pittman, L. Devisscher, H. Suemizu, N. D. Theise, L. Chiriboga, D. E. Cohen, , Y. P. de Jong
Abstract
Advanced non-alcoholic fatty liver disease (NAFLD) is a rapidly emerging global health problem associated with pre-disposing genetic polymorphisms, most strikingly an isoleucine to methionine substitution in patatin-like phospholipase domain-containing protein 3 (PNPLA3-I148M). Here, we study how human hepatocytes with PNPLA3 148I and 148M variants engrafted in the livers of chimeric mice respond to a hypercaloric Western-style diet. As early as 4 weeks, mice developed dyslipidemia, impaired glucose tolerance, and steatohepatitis selectively in the human graft, followed by pericellular fibrosis after 8 weeks of hypercaloric feeding. The PNPLA3 148M variant, either from a homozygous 148M human donor or overexpressed in a homozygous 148I donor background, caused widespread microvesicular steatosis and even more severe steatohepatitis. We conclude that PNPLA3 148M in human hepatocytes exacerbates NAFLD. These models will facilitate mechanistic studies into human genetic variants associated with advanced fatty liver diseases.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics
D. J. Sherman, L. Liu, … R. J. Deshaies·bioRxiv·Oct 13, 2023
- PNPLA3(148M) Promotes Hepatic Steatosis by Interfering with Triglyceride Hydrolysis Through a Gain-of-Function Mechanism
Yang Wang, Sen Hong, … Helen H. Hobbs·Journal of HepatologyPeer-reviewed·Nov 14, 2024
- PNPLA3-I148M is a Neomorph that Interferes with Two Primary Hepatic Triglyceride Clearance Pathways
David J. Sherman, Lei Liu, … Raymond J. Deshaies·Cell ReportsPeer-reviewed·Oct 1, 2025
- PNPLA3 I148M Reduces Hepatic Triacylglycerol Secretion and Mitigates Left Ventricular Diastolic Dysfunction in MASH Diet Mice
Andrew J. Butcko, Parsa Kamali, … Emilio P. Mottillo·bioRxiv·Apr 24, 2025
- Substrate-Specific Function of PNPLA3 Facilitates Hepatic VLDL-Triglyceride Secretion During Stimulated Lipogenesis
S. M. Johnson, H. Bao, … J. Liu·bioRxiv·Aug 30, 2023
- TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models
M. Longo, M. Meroni, … Paola Dongiovanni·Digestive and Liver DiseasePeer-reviewed·Feb 23, 2021